Ascendis Pharma (ASND) Tops Q2 EPS by 45c
Tweet
Share
E-mailGet Alerts ASND Hot Sheet
Join SI Premium – FREE
Ascendis Pharma (NASDAQ: ASND) reported Q2 EPS of (EUR0.82), EUR0.45 better than the analyst estimate of (EUR1.27). Revenue for the quarter came in at EUR158.05 million versus the consensus estimate of EUR142.38 million.
For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rockstar Energy founder seeks CEO role at Celsius Holdings
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- Minerva Neurosciences (NERV) Tops Q2 EPS by 5c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
